Funding sources None.
Molecular markers in melanoma
Version of Record online: 13 JAN 2014
© 2013 British Association of Dermatologists
British Journal of Dermatology
Volume 170, Issue 1, pages 31–35, January 2014
How to Cite
Kashani-Sabet, M. (2014), Molecular markers in melanoma. British Journal of Dermatology, 170: 31–35. doi: 10.1111/bjd.12493
Conflicts of interest Mohammed Kashani-Sabet has stock in Melanoma Diagnostics, Inc. Intellectual property covering markers developed in his laboratory was licensed to Myriad Genetics Laboratories.
- Issue online: 13 JAN 2014
- Version of Record online: 13 JAN 2014
- Accepted manuscript online: 1 JUL 2013 11:56AM EST
- Manuscript Accepted: 24 JUN 2013
The last few years have witnessed the dawn of the molecular era in melanoma treatment. With the advent of successful therapy targeting mutant BRAF, melanoma is leading the field of cancer research in the molecular approach to therapy of advanced disease. Attempting to keep pace with advances in therapy are advances in the molecular assessment of melanoma progression, facilitated by the availability of genome-wide approaches to interrogate the malignant phenotype. At the DNA level, this has included approaches such as comparative genomic hybridization. At the RNA level, this has consisted of gene expression profiling using various assay methodologies. In certain instances, markers identified using these platforms have been further examined and developed using fluorescence in situ hybridization and immunohistochemical analysis. In this article, we will review recent progress in the development of novel molecular markers for melanoma that are nearing clinical application. We will review developments in the molecular classification of melanoma, in the molecular diagnosis of melanoma, and in the molecular assessment of melanoma prognosis.